Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 7, 2011, Pages 4749-4756

  Olsen, Timothy W ^a,b   Feng, Xiao ^b   Wabner, Kathy ^b   Csaky, Karl ^c,d   Pambuccian, Stefan ^b   Douglas Cameron, J ^e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

^d TEXAS RETINA ASSOCIATES   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; VASCULOTROPIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ARTICLE; CHEMOLUMINESCENCE; CHOROID; DRUG ADMINISTRATION ROUTE; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GRANULOMATOUS VASCULITIS; HISTOLOGY; HISTOPATHOLOGY; IMMUNOHISTOLOGY; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA; SUPRACHOROIDAL DRUG ADMINISTRATION; SWINE; VITREOUS BODY; VITRITIS; ANIMAL; CATHETERIZATION; CELLULAR IMMUNITY; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; ELECTRONICS; FOLLOW UP; IMMUNOLOGY; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; PHOTORECEPTOR OUTER SEGMENT; RETINA MACULA DEGENERATION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; CATHETERIZATION; CHOROID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; IMMUNITY, CELLULAR; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MINIATURIZATION; RETINAL PHOTORECEPTOR CELL OUTER SEGMENT; RETINAL PIGMENT EPITHELIUM; SWINE; TREATMENT OUTCOME;

EID: 80052385883     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6291     Document Type: Article

References (20)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
2. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355: 1419-1431.
5. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled openlabel clinical study. Ophthalmology. 2006;113:2002, e2001-2012.
6. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047.
7. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349.
8. Rosenfeld PJ. Intravitreal Avastin: the low cost alternative to lucentis? Am J Ophthalmol. 2006;142:141-143.
9. Olsen TW, Aaberg SY, Geroski DH, Edelhauser HF. Human sclera: thickness and surface area. Am J Ophthalmol. 1998;125:237-241.
10. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36:1893-1903.
11. Pitkanen L, Ranta VP, Moilanen H, Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci. 2005;46:641-646.
12. Einmahl S, Savoldelli M, D'Hermies F, Tabatabay C, Gurny R, Behar-Cohen F. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest Ophthalmol Vis Sci. 2002;43:1533-1539.
13. Olsen TW, Feng X, Wabner K, et al. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. Am J Ophthalmol. 2006;142:777-787.
14. Lewis RA, von Wolff K, Tetz M, et al. Canaloplasty: circumferential viscodilation and tensioning of Schlemm canal using a flexible microcatheter for the treatment of open-angle glaucoma in adults: two-year interim clinical study results. J Cataract Refract Surg. 2009;35:814-824.
15. Ranta VP, Mannermaa E, Lummepuro K, et al. Barrier analysis of periocular drug delivery to the posterior segment. J Control Release. 2010;148:42-48
16. Bill A. The drainage of albumin from the uvea. Exp Eye Res. 1964;3:179-187.
17. Bill A. Movement of albumin and dextran through the sclera. Arch Ophthalmol. 1965;74:248-252.
18. Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2008;246:779-781.
19. Johnson D, Hollands H, Hollands S, Sharma S. Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study. Can J Ophthalmol. 2010;45:239-242.
20. Georgopoulos M, Polak K, Prager F, Prunte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol. 2009;93:457-462.